Our Commitment to Your Comfort: The ERAS Protocol
What Is ERAS?
ERAS is a multimodal perioperative care pathway designed to minimize surgical stress, reduce opioid use, and accelerate your return to normal function. Rather than relying on a one-size-fits-all approach, ERAS coordinates every phase of your care — preoperative, intraoperative, and postoperative — to work in concert for optimal outcomes. We treat pain and nausea through several complementary mechanisms simultaneously, so no single drug has to do all the work. Our ERAS protocol includes two breakthrough medications:
- Emend® (aprepitant) — a neurokinin-1 receptor antagonist administered before surgery to significantly reduce postoperative nausea and vomiting (PONV). Nausea is one of the most common complaints following anesthesia so Emend helps your recovery begin more comfortably.
- Journavx™ (suzetrigine) — a first-in-class selective Nav1.8 sodium channel blocker that provides targeted, non-opioid pain relief. Journavx represents a landmark advance in pain management, allowing us to deliver meaningful analgesia while minimizing or eliminating opioid use.
Our ERAS protocol isn’t simply a checklist — it’s a philosophy of proactive, patient-centered care backed by the latest clinical evidence. By integrating these therapies within a structured ERAS framework, we aim to provide a smoother perioperative experience, faster return to normal function, and improved overall patient satisfaction. Despite our best efforts, however, all patients must accept some risk of nausea and discomfort when undergoing surgery.